Loading...
Market
Will RYBREVANT® and LAZCLUZE™ be widely adopted by major US hospitals by end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Public announcements from major hospitals, healthcare publications, and Johnson & Johnson press releases
Story
FDA Approves J&J's RYBREVANT® and LAZCLUZE™ for EGFR-Mutated Lung Cancer
Aug 20, 2024, 11:18 AM
The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's chemotherapy-free combination therapy for treating a specific type of non-small cell lung cancer. The treatment, which includes RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), is designed as a first-line option for patients with EGFR-mutated advanced lung cancer. This marks Johnson & Johnson's first FDA approval for a chemotherapy-free lung cancer treatment.
View original story
Similar markets
Yes • 50%
No • 50%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Yes • 50%
No • 50%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%